glp-1 egfr cut off Updated algorithm to choose the optimum antidiabetic therapy between The biomarkers to watch when

We know there are people who are interested in addressing their weight but have been waiting on the sidelines for a medicine that was right for them, Ed Cinca, senior vice president of marketing & patient solutions at Novo Nordisk said in the press release

They concluded that incretin-based medications did not correlate with an increased risk of acute pancreatitis or pancreatic cancer compared to other oral anti-diabetic agents, which remained consistent across drug classification and duration of use [29,55]

At week 72, mean percentage weight loss was 15.0% with tirzepatide 5mg, 19.5% with 10mg, and 20.9% with 15mg, compared to just 3.1% with placebo

She answered some FAQs about the drugs, including whos eligible

Proc Natl Acad Sci U S A 100(25):1516615171

They only stimulate insulin release when blood sugar is elevated